The Atlantic Health System, an integrated health-care delivery system, recently announced a partnership with the Translational Genomics Research Institute, an affiliate of City of Hope, and Origin Commercial Ventures to create a new platform to deliver economically viable immunotherapies and other breakthrough cancer treatments to patients in the region through expedited access and novel payment options.
Eric Whitman, MD
“Cancer care is at its most promising point in the last 25 years. Yet, the industry is witnessing what happens when the science becomes so promising: it outstrips our financial and operational ability to effectively implement these advances in the clinical setting,” said Eric Whitman, MD, Medical Director of Atlantic Health System Cancer Care. “That is simply not an acceptable option for our patients, or the patients around the country who can benefit from these new treatments and technologies.”
The Breakthrough Oncology Accelerator flagship platform at Atlantic Health will create a model to enable health systems around the country to provide faster access and better patient outcomes by enabling clinicians and researchers to share their knowledge and provide more options for patients. Through the partnership, Atlantic Health System, Translational Genomics Research Institute, and Origin Commercial Ventures will leverage their proprietary platforms, expertise, and collaborations to identify and deploy those resources that best help oncologists meet the needs of their patients.
“Partnership with [Translational Genomics Research Institute and Origin Commercial Ventures] has already enhanced our clinical trial menu and changed cancer care in northern New Jersey, adding 15 novel clinical trials in the past year that are only available at a handful of sites in the world. In addition, [Translational Genomics Research Institute and Origin Commercial Ventures] will assist our cancer program in multiple other ways, providing us access to their core research strengths in genetic testing, liquid biopsies, scientific support services, and translational science,” continued Dr. Whitman. ■